Loading...
•
Mar 31, 2021
CareDx Q1 2021 Earnings Report
CareDx reported strong first quarter results and raised full year guidance.
Key Takeaways
CareDx achieved a record first quarter with total revenue of $67.4 million, a 76% increase year-over-year. The company raised its full year 2021 revenue guidance to $270 million to $280 million.
Total revenue reached $67.4 million, a 76% increase year-over-year.
Approximately 33,200 AlloSure and AlloMap patient results were provided, including 5,900 AlloSure Heart patient results.
Over 60 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol.
Completed a public offering, raising approximately $188.7 million in net proceeds, increasing cash, cash equivalents and marketable securities to $374.3 million.
Revenue by Segment
Forward Guidance
CareDx expects full year 2021 revenue to be in the range of $270 million to $280 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...